TGTX (TG Therapeutics) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TGTX TG Therapeutics Inc TGTX
82 GF Score
Price $54.86
GF Value $59.70
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is TG Therapeutics FFO per Share?

FFO per Share only applies to REITs.

TGTX
82GF Score
TG Therapeutics Inc TGTX
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TG Therapeutics (TGTX) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of $54.86 is trading 8.1% below its estimated GF Value™ of $59.70. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for TGTX:

  • FFO per Share:
  • GF Value™: $59.70 vs. price of $54.86 (8.1% below fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges 1TGTX:ItalyNKB2:Germany
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score

Get the complete analysis for TGTX

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.86
Price
$59.70
GF Value